ELIAS Animal Health
Clinical-stage veterinary oncology company developing personalized immunotherapies for canine cancer. The organization develops autologous vaccine-primed adoptive T cell therapies, conducts multi-center clinical trials and registries, coordinates apheresis collection with partner centers, and in-licenses additional immunotherapy modalities for veterinary development and commercialization.
Industries
Nr. of Employees
small (1-50)
ELIAS Animal Health
Products
Autologous vaccine-primed adoptive cell therapy for canine osteosarcoma
A personalized treatment combining an autologous tumor-cell vaccine to prime immune responses followed by collection, ex vivo activation/expansion and reinfusion of the patient’s T cells to target osteosarcoma.
ELIAS Cancer Immunotherapy
A canine cancer immunotherapy protocol developed by ELIAS Animal Health, designed to treat canine osteosarcoma using adoptive cell therapy involving killer T cells.
ELIAS Cancer Immunotherapy (ECI®)
The ELIAS Cancer Immunotherapy (ECI®) combines an autologous vaccine with cell therapy to target a patient’s unique cancer cells. This personalized approach can improve clinical outcomes and provide a better quality of life for canine patients. ECI® is USDA-approved for treatment of canine osteosarcoma and, as an autologous prescription product, can also be used by licensed veterinarians to treat other cancers.
ELIAS Cancer Immunotherapy (ECI 4)
A type of adoptive cell therapy designed to stimulate the patient's immune system to recognize and eliminate cancer cells using attenuated autologous cancer cell vaccines to prime immune cells to cancer-specific antigens.
ELI352 – Oncolytic Virotherapy
An oncolytic virotherapy using a vaccinia viral strain that selectively replicates in cancer cells causing apoptosis. It is being developed to treat a variety of tumoral cancers in companion animals including osteosarcoma, oral melanoma, lymphoma, and mast cell tumors.
V-VET1
Genelux Corporation’s clinical-stage animal health product candidate, a vaccinia viral strain that selectively replicates in cancer cells to cause apoptosis.
Autologous vaccine-primed adoptive cell therapy for canine osteosarcoma
A personalized treatment combining an autologous tumor-cell vaccine to prime immune responses followed by collection, ex vivo activation/expansion and reinfusion of the patient’s T cells to target osteosarcoma.
ELIAS Cancer Immunotherapy
A canine cancer immunotherapy protocol developed by ELIAS Animal Health, designed to treat canine osteosarcoma using adoptive cell therapy involving killer T cells.
ELIAS Cancer Immunotherapy (ECI®)
The ELIAS Cancer Immunotherapy (ECI®) combines an autologous vaccine with cell therapy to target a patient’s unique cancer cells. This personalized approach can improve clinical outcomes and provide a better quality of life for canine patients. ECI® is USDA-approved for treatment of canine osteosarcoma and, as an autologous prescription product, can also be used by licensed veterinarians to treat other cancers.
ELIAS Cancer Immunotherapy (ECI 4)
A type of adoptive cell therapy designed to stimulate the patient's immune system to recognize and eliminate cancer cells using attenuated autologous cancer cell vaccines to prime immune cells to cancer-specific antigens.
ELI352 – Oncolytic Virotherapy
An oncolytic virotherapy using a vaccinia viral strain that selectively replicates in cancer cells causing apoptosis. It is being developed to treat a variety of tumoral cancers in companion animals including osteosarcoma, oral melanoma, lymphoma, and mast cell tumors.
V-VET1
Genelux Corporation’s clinical-stage animal health product candidate, a vaccinia viral strain that selectively replicates in cancer cells to cause apoptosis.
Services
Coordination with veterinary oncologists and specialty hospitals to deliver personalized autologous vaccine-primed adoptive T cell therapy to canine patients.
Organization of apheresis appointments and specimen transfer through partner centers (including mobile apheresis) to support collection of patient immune cells for processing.
Sponsorship and operational management of multi-center clinical trials and investigator collaborations (including randomized pivotal trials and single-arm pilot studies for indications such as oral melanoma), with financial assistance programs to support participant enrollment.
Coordination with veterinary oncologists and specialty hospitals to deliver personalized autologous vaccine-primed adoptive T cell therapy to canine patients.
Organization of apheresis appointments and specimen transfer through partner centers (including mobile apheresis) to support collection of patient immune cells for processing.
Sponsorship and operational management of multi-center clinical trials and investigator collaborations (including randomized pivotal trials and single-arm pilot studies for indications such as oral melanoma), with financial assistance programs to support participant enrollment.
Expertise Areas
- Adoptive cell therapy development
- Autologous cancer vaccine development
- Veterinary clinical trial management
- Apheresis procedures and logistics for veterinary patients
Key Technologies
- Autologous adoptive T cell therapy
- Autologous tumor-cell vaccination
- Apheresis-based cellular collection
- Ex vivo T cell activation and expansion
News & Updates
Regulatory approval granted by the USDA Center for Veterinary Biologics for an autologous adoptive cell therapy indicated for treatment of canine osteosarcoma.
Interim results from a study combining a single dose of chemotherapy with vaccine-primed adoptive cell therapy demonstrated improved outcomes in canine osteosarcoma and were presented at a major veterinary conference.
Initiation of a multi-center single-arm pilot study evaluating adoptive T cell therapy combined with surgery and radiotherapy (when indicated) for dogs with newly diagnosed oral malignant melanoma; financial assistance provided to participants.
USDA Center for Veterinary Biologics determined pivotal combined safety and efficacy study data demonstrated a reasonable expectation of efficacy for an adoptive cell therapy in canine osteosarcoma (two-arm, n=100 field study).
Mechanism-of-action in vitro data showed that vaccine-primed T cells mount a significant immune response and exhibit cytotoxic activity against target cancer cells.
Company CEO appeared on a podcast to discuss how the adoptive cell therapy works, the role of the immune system in treatment success, and the rationale for focusing development on canine osteosarcoma.
Regulatory approval granted by the USDA Center for Veterinary Biologics for an autologous adoptive cell therapy indicated for treatment of canine osteosarcoma.
Interim results from a study combining a single dose of chemotherapy with vaccine-primed adoptive cell therapy demonstrated improved outcomes in canine osteosarcoma and were presented at a major veterinary conference.
Initiation of a multi-center single-arm pilot study evaluating adoptive T cell therapy combined with surgery and radiotherapy (when indicated) for dogs with newly diagnosed oral malignant melanoma; financial assistance provided to participants.
USDA Center for Veterinary Biologics determined pivotal combined safety and efficacy study data demonstrated a reasonable expectation of efficacy for an adoptive cell therapy in canine osteosarcoma (two-arm, n=100 field study).
Mechanism-of-action in vitro data showed that vaccine-primed T cells mount a significant immune response and exhibit cytotoxic activity against target cancer cells.
Company CEO appeared on a podcast to discuss how the adoptive cell therapy works, the role of the immune system in treatment success, and the rationale for focusing development on canine osteosarcoma.